CU20190067A7 - Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents

Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)

Info

Publication number
CU20190067A7
CU20190067A7 CU2019000067A CU20190067A CU20190067A7 CU 20190067 A7 CU20190067 A7 CU 20190067A7 CU 2019000067 A CU2019000067 A CU 2019000067A CU 20190067 A CU20190067 A CU 20190067A CU 20190067 A7 CU20190067 A7 CU 20190067A7
Authority
CU
Cuba
Prior art keywords
ahr
modulators
aryl hydrocarbon
hydrocarbon receptor
pirrolo
Prior art date
Application number
CU2019000067A
Other languages
English (en)
Inventor
Michael Albers
Ulrich Deuschle
Thomas Hoffmann
Christoph Steeneck
Original Assignee
Phenex Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phenex Pharmaceuticals Ag filed Critical Phenex Pharmaceuticals Ag
Publication of CU20190067A7 publication Critical patent/CU20190067A7/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La presente invención se refiere a compuestos químicos derivados de 1H-pirrolo [3,2-c] piridina según la fórmula (I)</p> <p>ESPACIO PARA LA FÓRMULA</p> <p>que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. Dichos compuestos son útiles para el tratamiento y/o profilaxis de enfermedades y/o condiciones como el cáncer, a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.</p>
CU2019000067A 2017-02-01 2018-02-01 Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr) CU20190067A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17000157 2017-02-01
PCT/EP2018/052538 WO2018141855A1 (en) 2017-02-01 2018-02-01 Aryl hydrocarbon receptor (ahr) modulator compounds

Publications (1)

Publication Number Publication Date
CU20190067A7 true CU20190067A7 (es) 2020-03-04

Family

ID=57960222

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2019000067A CU20190067A7 (es) 2017-02-01 2018-02-01 Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)

Country Status (26)

Country Link
US (1) US11376241B2 (es)
EP (1) EP3577115B1 (es)
JP (1) JP2020505467A (es)
KR (1) KR20190113902A (es)
CN (1) CN110234650A (es)
AR (1) AR110790A1 (es)
AU (1) AU2018216955B2 (es)
BR (1) BR112019015704A2 (es)
CA (1) CA3051034A1 (es)
CL (1) CL2019002112A1 (es)
CO (1) CO2019007882A2 (es)
CR (1) CR20190393A (es)
CU (1) CU20190067A7 (es)
EA (1) EA201991600A1 (es)
EC (1) ECSP19055179A (es)
IL (1) IL268082A (es)
JO (1) JOP20190176A1 (es)
MX (1) MX2019008993A (es)
NI (1) NI201900075A (es)
PE (1) PE20191479A1 (es)
PH (1) PH12019550136A1 (es)
SG (1) SG11201906959RA (es)
TW (1) TWI674260B (es)
UA (1) UA122746C2 (es)
UY (1) UY37590A (es)
WO (1) WO2018141855A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
JP7382348B2 (ja) 2018-02-06 2023-11-16 アイディアヤ バイオサイエンシーズ,インコーポレイティド AhRモジュレータ
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN109813913B (zh) * 2019-01-31 2021-11-09 中国医学科学院肿瘤医院 芳烃受体(AhR)在预测免疫治疗效果中的应用
US12473262B2 (en) 2019-07-30 2025-11-18 Oregon State University Aryl hydrocarbon receptor activators
KR102351515B1 (ko) 2019-12-17 2022-01-14 (주)수파드엘릭사 아릴 탄화수소 수용체의 활성을 억제하는 폡타이드 및 이를 이용하는 화장료 조성물
WO2021148628A1 (en) * 2020-01-23 2021-07-29 Phenex Pharmaceuticals Ag Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
US20240124444A1 (en) * 2020-12-28 2024-04-18 Celgene Corporation Heterocyclic Compounds and Their Use for Parasitic Diseases
CN115572282B (zh) * 2021-07-05 2024-07-09 华东理工大学 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用
US20260007652A1 (en) * 2022-10-14 2026-01-08 Oregon State University Selective Modulators of AhR-Regulated Transcription and Method for Using Such Modulators to Treat Cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992002500A1 (fr) 1990-07-31 1992-02-20 Teikoku Hormone Mfg. Co., Ltd. Derive de 2-phenylindole
KR20000057137A (ko) 1996-11-19 2000-09-15 스티븐 엠. 오드레 아릴 및 헤테로아릴로 치환된 융합 피롤 항염증제
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU2006314649A1 (en) 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Azaindole-2-carboxamide derivatives
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2011046954A1 (en) 2009-10-13 2011-04-21 Ligand Pharmaceuticals Inc. Hematopoietic growth factor mimetic small molecule compounds and their uses
US20130338201A1 (en) * 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
AU2010313622B2 (en) * 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
PL2531501T3 (pl) 2010-02-03 2014-05-30 Takeda Pharmaceuticals Co Inhibitory kinazy 1 regulującej sygnał apoptotyczny
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
AU2011282776B2 (en) 2010-07-27 2014-06-12 Boston Medical Center Corporation Aryl hydrocarbon receptor (AhR) modifiers as novel cancer therapeutics
GB201104267D0 (en) * 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
CA2888369A1 (en) 2012-10-17 2014-04-24 F. Hoffmann-La Roche Ag 6-aminoindole derivatives as trp channel antagonists
MX365640B (es) 2012-12-21 2019-06-10 Plexxikon Inc Compuestos y metodos para la modulacion de quinasas y sus indicaciones.
TWI674260B (zh) 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
TWI752155B (zh) 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TW201835070A (zh) 2017-02-21 2018-10-01 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物

Also Published As

Publication number Publication date
JP2020505467A (ja) 2020-02-20
WO2018141855A1 (en) 2018-08-09
NI201900075A (es) 2019-10-30
EP3577115A1 (en) 2019-12-11
AU2018216955A1 (en) 2019-08-01
MX2019008993A (es) 2019-12-19
AR110790A1 (es) 2019-05-02
EA201991600A1 (ru) 2020-03-10
ECSP19055179A (es) 2019-08-30
BR112019015704A2 (pt) 2020-04-07
PH12019550136A1 (en) 2020-03-02
CO2019007882A2 (es) 2019-10-09
SG11201906959RA (en) 2019-08-27
US11376241B2 (en) 2022-07-05
CL2019002112A1 (es) 2019-12-20
JOP20190176A1 (ar) 2019-07-15
CA3051034A1 (en) 2018-08-09
TW201838991A (zh) 2018-11-01
EP3577115B1 (en) 2020-12-02
IL268082A (en) 2019-09-26
PE20191479A1 (es) 2019-10-16
TWI674260B (zh) 2019-10-11
UY37590A (es) 2018-02-28
CR20190393A (es) 2019-10-21
AU2018216955B2 (en) 2020-09-17
CN110234650A (zh) 2019-09-13
US20210260045A1 (en) 2021-08-26
KR20190113902A (ko) 2019-10-08
UA122746C2 (uk) 2020-12-28

Similar Documents

Publication Publication Date Title
CU20190067A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo [3,2-c] piridinas como moduladores del receptor de hidrocarburos de arilo (ahr)
CU20190069A7 (es) Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr)
NI201800075A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos.
CL2020001546A1 (es) Compuestos de 4-azaindol.
PH12019550155A1 (en) ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CO2017005959A2 (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CO2017004074A2 (es) Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii
DOP2016000211A (es) Pirazinas moduladoras de gpr6
MX2018005305A (es) Nuevos antiestrogenos heterociclicos.
MX2016009219A (es) Compuestos heteroarilo bicíclicos sustituidos como agonistas rxr.
CO2017005118A2 (es) Nuevos compuestos hidrosolubles derivados del bencimidazol, utiles para el tratamiento de la fasciolosis